and sometimes several times a day. Furthermore, it is estimated that approximately 15 million intraocular injections are performed every year for the treatment of pathologies of the retina.
But despite all these treatments, the last WHO world report on vision2 estimates that between 250M and 300M people lose sight because of diseases for which pharmaceutical treatments exist.
Pharm D., MBA 15 years of business experience in the field of ophthalmic industry across different roles and functions (general management, subsidiaries establishment, global business development, market access, and government price negotiations).
Ph.D, Pharm D. & MBA, 20 years international experience in drug development & drug delivery. Former Head of development (CMC, preclinical safety and regulatory) at Stallergenes Greer and NextPharma and R&D Program Director at Novartis
Ph.D in Chemistry, Project Leader in CMC and expert in polymer synthesis and in chemical analytical methods development.
Ph.D & Pharm D., expert in ophthalmic drug development. Former R&D manager in 2 ophthalmology. start-ups (Novagali, Horama) & in industry (Santen).
MBBS(Hons), MBA, FFPM, FRCP(Glasg), LLM, has broad experience across medical and regulatory affairs and pharmacovigilance in the global pharmaceutical industry for over two decades.
M.Sc. & MBA (HEC), is an experienced CFO with an in-depth international exposure. He hold various CFO positions with CAC40 listed companies as well as with major global businesses.